Stacker Steven A, Williams Richard A, Achen Marc G
Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Victoria, Australia.
APMIS. 2004 Jul-Aug;112(7-8):539-49. doi: 10.1111/j.1600-0463.2004.apm11207-0812.x.
Understanding the complex process of tumor metastasis is a problem which has challenged both clinician and scientist for well over 100 years. Defining molecular markers which reflect the metastatic potential of a tumor has also proved elusive. Recently, members of the vascular endothelial growth factor (VEGF) family of glycoproteins have been demonstrated to be potent mediators of both blood vessel and lymphatic vessel formation in the context of tumor biology. Experimental studies in animal models combined with extensive clinicopathological data provide a compelling case indicating that members of the VEGF family play a key role in the formation of metastases in a broad range of solid tumors. The question of whether VEGF signaling pathways can now serve as therapeutic targets alone, or in combination with other forms of anti-cancer agents, needs to be addressed.
理解肿瘤转移的复杂过程是一个在100多年来一直困扰临床医生和科学家的问题。确定反映肿瘤转移潜能的分子标志物也一直难以实现。最近,糖蛋白血管内皮生长因子(VEGF)家族成员已被证明在肿瘤生物学背景下是血管和淋巴管形成的有效介质。动物模型的实验研究与广泛的临床病理数据相结合,有力地表明VEGF家族成员在多种实体瘤转移形成中起关键作用。VEGF信号通路现在是否可以单独作为治疗靶点,或者与其他形式的抗癌药物联合使用,这个问题需要得到解决。